

CLAIM LISTING

1-274 (Canceled)

275. (Currently Amended) An isolated multimeric composition comprising a binding matrix and more than one monomeric unit, wherein each monomeric unit comprises two elements covalently attached to one another, wherein a first element is a protein, wherein said protein is a ligand to a cell surface receptor, wherein a second element is a single-stranded polynucleotide and wherein each monomeric unit is separately attached to said binding matrix through said second element via hydrogen bonding between said single-stranded polynucleotide of said monomeric unit and said binding matrix, wherein said binding matrix is a polynucleotide[[,]] comprising a sequence[[s]] complementary to said single-stranded polynucleotide.

276-288 (Canceled)

289. (Withdrawn) A process for delivering the multimeric complex of claim 275 to a subject comprising introducing the complex to one or more cells ex vivo and administering said cells to said subject.

290. (Withdrawn) A process for delivering the multimeric complex of claim 275 to a subject comprising administering said complex to said subject.

291-295 (Canceled)

296. (Previously Presented) The composition according to claim 275, wherein said ligand to a cell surface receptor is a hormone.

Elazar Rabbani et al.
Serial No.: 08/978,634
Filed: November 25, 1997
Page 3 Reply To March 7, 2011 Office Action

297. (Previously Presented) The composition according to claim 296, wherein said hormone is insulin.

298. (Withdrawn) The composition according to claim 275, wherein said ligand to a cell surface receptor is a growth factor.

299. (Withdrawn) The composition according to claim 298, wherein said growth factor is erythropoietin.

300. (Withdrawn) The composition according to claim 275, wherein said ligand to a cell surface receptor is a cytokine.

301. (Withdrawn) The composition according to claim 300, wherein said cytokine is a lymphokine.

o